From MarketBeat:

Regeneron Pharmaceuticals (NASDAQ:REGN) saw its rating downgraded to a “buy” by StockNews.com. Despite this, Regeneron Pharmaceuticals’ stock price traded up 0.1% on Friday, hitting $913.17. The company has received mixed reviews from analysts, with one sell rating, six hold ratings, and twenty buy ratings. Institutional investors currently own 84.15% of Regeneron Pharmaceuticals’ stock.

Regeneron Pharmaceuticals released its quarterly earnings data on November 2nd, reporting $10.17 earnings per share. The company’s revenue for the quarter was $3.36 billion, up 14.5% compared to the same period last year. Analysts project Regeneron Pharmaceuticals will post $36.28 EPS for the current year. The company’s stock had a trading volume of 486,055 shares on Friday.

In recent insider transactions, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock at an average price of $827.90 on November 7th. Also, Director Huda Y. Zoghbi sold 1,000 shares of the company’s stock on October 13th at an average price of $850.00.

Institutional investors have adjusted their holdings of Regeneron Pharmaceuticals stock recently. This includes Annis Gardner Whiting Capital Advisors LLC, Sunbelt Securities Inc., Sutton Wealth Advisors Inc., and BerganKDV Wealth Management LLC.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for various diseases globally. The company’s most notable product is EYLEA injection, used to treat a range of eye conditions. Regeneron Pharmaceuticals is currently rated a “Moderate Buy” and has an average price target of $908.12.



Read more: Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded to “Buy” at StockNews.com